专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11835503B2 TMA-formation inhibitor treatment for elevated TMA-containing compound diseases 有权
公开(公告)号：US11835503B2
公开(公告)日：2023-12-05
申请号：US17234229
申请日：2021-04-19
申请人： The Cleveland Clinic Foundation
发明人： Stanley L. Hazen , Zeneng Wang , Bruce S. Levison
IPC分类号： G01N30/88 , C12Q1/18 , G01N33/68 , A61K31/4164 , A61K31/43 , A61K31/7036 , G01N30/72 , C12Q1/02 , A61K31/496
CPC分类号： G01N30/88 , A61K31/4164 , A61K31/43 , A61K31/496 , A61K31/7036 , C12Q1/025 , C12Q1/18 , G01N33/6893 , G01N30/7233 , G01N2030/8813 , G01N2030/8822 , G01N2800/04 , G01N2800/042 , G01N2800/044 , G01N2800/32 , G01N2800/323 , G01N2800/50 , G01N2800/52
摘要： The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.

2. 发明授权

US10551372B2 Trimethylamine compounds as risk predictors of cardiovascular disease 有权
公开(公告)号：US10551372B2
公开(公告)日：2020-02-04
申请号：US15234050
申请日：2016-08-11
申请人： The Cleveland Clinic Foundation
发明人： Stanley L. Hazen , Zeneng Wang , Bruce S. Levison
IPC分类号： G01N24/00 , G01N33/49 , G01N33/92 , G01N33/493 , H01J49/00
摘要： Methods of characterizing a test subject's risk of having or developing cardiovascular disease are provided. The methods include using an analytic device to determine levels of choline-related trimethylamine-containing compounds such as trimethylamine N-oxide, choline, or betaine in a biological sample obtained from the subject and comparing the levels of the choline-related trimethylamine-containing compound in the subject's biological sample to a control value. The test subject's risk of having cardiovascular disease is then characterized as higher if the levels of the choline-related trimethylamine-containing compound are higher than the control value. Also provided are methods of identifying a subject at risk of experiencing a complication of atherosclerotic cardiovascular disease, and methods of evaluating the efficacy of a cardiovascular therapeutic agent in a subject with cardiovascular disease using levels of choline-related trimethylamine-containing compounds.

3. 发明申请

US20160349236A1 TRIMETHYLAMINE COMPOUNDS AS RISK PREDICTORS OF CARDIOVASCULAR DISEASE 审中-公开
标题翻译：作为心血管疾病风险预防剂的三甲胺化合物
公开(公告)号：US20160349236A1
公开(公告)日：2016-12-01
申请号：US15234050
申请日：2016-08-11
申请人： The Cleveland Clinic Foundation
发明人： Stanley L. Hazen , Zeneng Wang , Bruce S. Levison
IPC分类号： G01N33/49 , H01J49/00 , G01N33/493
摘要： Methods of characterizing a test subject's risk of having or developing cardiovascular disease are provided. The methods include using an analytic device to determine levels of choline-related trimethylamine-containing compounds such as trimethylamine N-oxide, choline, or betaine in a biological sample obtained from the subject and comparing the levels of the choline-related trimethylamine-containing compound in the subject's biological sample to a control value. The test subject's risk of having cardiovascular disease is then characterized as higher if the levels of the choline-related trimethylamine-containing compound are higher than the control value. Also provided are methods of identifying a subject at risk of experiencing a complication of atherosclerotic cardiovascular disease, and methods of evaluating the efficacy of a cardiovascular therapeutic agent in a subject with cardiovascular disease using levels of choline-related trimethylamine-containing compounds.
摘要翻译：提供测试受试者患有或发展心血管疾病风险的方法。所述方法包括使用分析装置来确定从受试者获得的生物样品中胆碱相关的含三甲胺的化合物如三甲胺N-氧化物，胆碱或甜菜碱的含量，并比较胆碱相关的含三甲胺的化合物在受试者的生物样本中达到对照值。如果胆碱相关的含三甲胺的化合物的含量高于对照值，则测试对象具有心血管疾病的风险的特征就更高。还提供了鉴定患有动脉粥样硬化性心血管疾病并发症风险的受试者的方法，以及使用胆碱相关的含三甲胺化合物水平的心血管疾病患者评价心血管治疗剂的功效的方法。

4. 发明申请

US20220065829A1 TRIMETHYLAMINE-CONTAINING COMPOUNDS FOR DIAGNOSIS AND PREDICTION OF DISEASE 有权
公开(公告)号：US20220065829A1
公开(公告)日：2022-03-03
申请号：US17234229
申请日：2021-04-19
申请人： The Cleveland Clinic Foundation
发明人： Stanley L. Hazen , Zeneng Wang , Bruce S. Levison
IPC分类号： G01N30/88 , C12Q1/02 , C12Q1/18 , G01N33/68 , A61K31/4164 , A61K31/43 , A61K31/496 , A61K31/7036
摘要： The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.

5. 发明申请

US20200173979A1 TRIMETHYLAMINE COMPOUNDS AS RISK PREDICTORS OF CARDIOVASCULAR DISEASE 审中-公开
公开(公告)号：US20200173979A1
公开(公告)日：2020-06-04
申请号：US16781409
申请日：2020-02-04
申请人： The Cleveland Clinic Foundation
发明人： Stanley L. Hazen , Zeneng Wang , Bruce S. Levison
IPC分类号： G01N33/49 , G01N33/68 , H01J49/00 , G01N33/493 , G01N33/92
摘要： Methods of characterizing a test subject's risk of having or developing cardiovascular disease are provided. The methods include using an analytic device to determine levels of choline-related trimethylamine-containing compounds such as trimethylamine N-oxide, choline, or betaine in a biological sample obtained from the subject and comparing the levels of the choline-related trimethylamine-containing compound in the subject's biological sample to a control value. The test subject's risk of having cardiovascular disease is then characterized as higher if the levels of the choline-related trimethylamine-containing compound are higher than the control value. Also provided are methods of identifying a subject at risk of experiencing a complication of atherosclerotic cardiovascular disease, and methods of evaluating the efficacy of a cardiovascular therapeutic agent in a subject with cardiovascular disease using levels of choline-related trimethylamine-containing compounds.

6. 发明授权

US12055535B2 Trimethylamine compounds as risk predictors of cardiovascular disease 有权
公开(公告)号：US12055535B2
公开(公告)日：2024-08-06
申请号：US16781409
申请日：2020-02-04
申请人： The Cleveland Clinic Foundation
发明人： Stanley L. Hazen , Zeneng Wang , Bruce S. Levison
IPC分类号： G01N33/48 , G01N33/483 , G01N33/49 , G01N33/493 , G01N33/68 , G01N33/92 , H01J49/00
CPC分类号： G01N33/49 , G01N33/493 , G01N33/6893 , G01N33/92 , H01J49/0036 , G01N2800/32 , G01N2800/323 , G01N2800/50 , G01N2800/52 , G01N2800/56 , Y10T436/174614
摘要： Methods of characterizing a test subject's risk of having or developing cardiovascular disease are provided. The methods include using an analytic device to determine levels of choline-related trimethylamine-containing compounds such as trimethylamine N-oxide, choline, or betaine in a biological sample obtained from the subject and comparing the levels of the choline-related trimethylamine-containing compound in the subject's biological sample to a control value. The test subject's risk of having cardiovascular disease is then characterized as higher if the levels of the choline-related trimethylamine-containing compound are higher than the control value. Also provided are methods of identifying a subject at risk of experiencing a complication of atherosclerotic cardiovascular disease, and methods of evaluating the efficacy of a cardiovascular therapeutic agent in a subject with cardiovascular disease using levels of choline-related trimethylamine-containing compounds.

7. 发明授权

US10983100B2 Trimethylamine-containing compounds for diagnosis and prediction of disease 有权
公开(公告)号：US10983100B2
公开(公告)日：2021-04-20
申请号：US16265571
申请日：2019-02-01
申请人： The Cleveland Clinic Foundation
发明人： Stanley L. Hazen , Zeneng Wang , Bruce S. Levison
IPC分类号： G01N33/68 , A61K31/4164 , A61K31/43 , A61K31/496 , A61K31/7036 , G01N30/72 , G01N30/88 , C12Q1/02 , C12Q1/18
摘要： The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式